guest ::
| Home > Publications database > Modern radiotherapy of primary prostate cancer.[Moderne Strahlentherapie des primären Prostatakarzinoms.] |
| Home > Publications database > Modern radiotherapy of primary prostate cancer.[Moderne Strahlentherapie des primären Prostatakarzinoms.] |
| Journal Article | DKFZ-2023-00598 |
; ;
2023
Springer
Heidelberg
Abstract: Prostate cancer (PCa) is the most frequent malignant disease in men. While patients with a low risk profile can be actively monitored (watchful waiting), radiotherapy and surgery are equivalent therapeutic options for patients with an intermediate or high risk profile. Modern radiotherapy allows a reduction in treatment time to 2–4 weeks via hypofractionation or stereotactic body radiotherapy (SBRT), is associated with a low rate of adverse events, and enables personalized treatment adapted to the individual anatomy and tumor geometry. Information from multiparametric MRI (mpMRI) and positron-emission tomography with tracers targeting the prostate-specific membrane antigen (PSMA-PET) can be considered during treatment planning. Using focal dose escalation, the radiation dose to the tumor in the prostate can be increased, without further exposure of proximal organs. The HypoFocal-SBRT study, a multicentric phase III trial funded by the National Decade Against Cancer, is investigating the possible benefit of SBRT in five fractions with dose escalation to the intraprostatic tumor lesions defined by mpMRT and PSMA-PET. The aim of this study is to further improve the recurrence-free survival of patients with localized PCa of intermediate and high risk profile while simultaneously reducing the treatment time.
|
The record appears in these collections: |
